Larimar Therapeutics 관리

관리 기준 확인 2/4

Larimar Therapeutics CEO는 Carole Ben-Maimon, May2020 에 임명되었습니다 의 임기는 4.5 년입니다. 총 연간 보상은 $ 3.14M, 17.8% 로 구성됩니다. 17.8% 급여 및 82.2% 보너스(회사 주식 및 옵션 포함). 는 $ 696.56K 가치에 해당하는 회사 주식의 0.18% 직접 소유합니다. 696.56K. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.3 년입니다.

주요 정보

Carole Ben-Maimon

최고 경영자

US$3.1m

총 보상

CEO 급여 비율	17.8%
CEO 임기	4.5yrs
CEO 소유권	0.2%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	4.3yrs

최근 관리 업데이트

Recent updates

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Oct 07

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Aug 09

Larimar Therapeutics: More Data Still Needed

Jul 15

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

May 31

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Nov 13

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

May 19

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 02

Laramar Therapeutics issued patent for lead pipeline candidate

Oct 20

Larimar Therapeutics prices ~$70M stock offering

Sep 14

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Sep 02

Larimar Therapeutics GAAP EPS of -$0.47

Aug 11

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Mar 21

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Dec 18

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

May 26

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Feb 08

CEO 보상 분석

Carole Ben-Maimon 의 보수는 Larimar Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$65m
Jun 30 2024	n/a	n/a	-US$58m
Mar 31 2024	n/a	n/a	-US$45m
Dec 31 2023	US$3m	US$560k	-US$37m
Sep 30 2023	n/a	n/a	-US$33m
Jun 30 2023	n/a	n/a	-US$33m
Mar 31 2023	n/a	n/a	-US$33m
Dec 31 2022	US$2m	US$528k	-US$35m
Sep 30 2022	n/a	n/a	-US$35m
Jun 30 2022	n/a	n/a	-US$44m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	US$2m	US$510k	-US$51m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$49m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$5m	US$268k	-US$42m

보상 대 시장: Carole 의 총 보상 ($USD 3.14M )은 US 시장( $USD 2.14M ).

보상과 수익: 회사가 수익성이 없는 동안 Carole 의 보상이 증가했습니다.

CEO

Carole Ben-Maimon (65 yo)

4.5yrs

테뉴어

US$3,137,432

보상

Dr. Carole S. Ben-Maimon, M.D., is President, Chief Executive Officer and Director at Larimar Therapeutics, Inc. since May 28, 2020. She was Chief Executive Officer, President and Director at Chondrial The...

리더십 팀

이름	위치	테뉴어	보상	소유권
Carole Ben-Maimon	CEO, President & Director	4.5yrs	US$3.14m	0.18% $ 696.6k
Michael Celano	Secretary & CFO	4.5yrs	US$1.42m	0.087% $ 343.4k
Gopi Shankar	Chief Development Officer	1.8yrs	US$1.43m	0.0078% $ 30.8k
John Berman	Vice President of Finance & Administration	1.3yrs	데이터 없음	데이터 없음
Jennifer Johansson	Vice President of Legal & Compliance	7.9yrs	데이터 없음	데이터 없음
Russell Clayton	Chief Medical Officer	1.3yrs	데이터 없음	데이터 없음
Francis Conway	VP & Controller	4.3yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 관리: LRMR 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Carole Ben-Maimon	CEO, President & Director	4.5yrs	US$3.14m	0.18% $ 696.6k
Jonathan Leff	Independent Director	4.5yrs	US$79.96k	데이터 없음
Jeffrey Sherman	Independent Director	1.1yrs	US$56.43k	0% $ 0
Frank Thomas	Independent Director	10.4yrs	US$86.21k	0.0031% $ 12.3k
Thomas Hamilton	Independent Director	4.5yrs	US$77.77k	0.89% $ 3.5m
Joseph Truitt	Independent Chairman of the Board	4.5yrs	US$114.96k	0.0043% $ 16.9k
Giovanni Manfredi	Member of Scientific Advisory Board	4.1yrs	데이터 없음	데이터 없음
Mark Payne	Member of Scientific Advisory Board	4.1yrs	데이터 없음	데이터 없음
Marni Falk	Member of Scientific Advisory Board	4.1yrs	데이터 없음	데이터 없음
Jill Ostrem	Member of Scientific Advisory Board	2.2yrs	데이터 없음	데이터 없음

4.3yrs

평균 재임 기간

57.5yo

평균 연령

경험이 풍부한 이사회: LRMR 의 이사회는 경험(평균 재직 기간 4.3 년)으로 간주됩니다.

Larimar Therapeutics 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

High number of new and inexperienced directors

CEO, President & Director recently bought US$100k worth of stock

High number of new and inexperienced directors

Recent updates

Larimar Therapeutics, Inc. Presents Additional Data from Phase 1 Studies and Phase 2 Dose Exploration Study Supporting the Nomlabofusp Clinical Program at ICAR 2024

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics, Inc. Announces Data from the Nomlabofusp Phase 1 Studies and Phase 2 Dose Exploration Study

Larimar Therapeutics (NASDAQ:LRMR) Is In A Good Position To Deliver On Growth Plans

Larimar Therapeutics: More Data Still Needed

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Small Cap Comp Value Index

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

United States Food and Drug Administration Selects Larimar Therapeutics, Inc. to Participate in Start Pilot Program for Nomlabofusp in Friedreich's Ataxia

Larimar Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Revenue and earnings growth

Larimar Therapeutics Announces the Dosing of the First Patient in Long-Term Open Label Extension Study for Nomlabofusp in Patients with Friedreich’S Ataxia

New minor risk - Shareholder dilution

Larimar Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000005 million.

Larimar Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $50 million.

Price target increased by 41% to US$16.24

Larimar Therapeutics, Inc. Reports Positive Top-Line Data from Phase 2 Dose Exploration Study from 25 Mg and 50 Mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia

We're Hopeful That Larimar Therapeutics (NASDAQ:LRMR) Will Use Its Cash Wisely

Larimar Therapeutics, Inc. Appoints Dr. Jeffery W. Sherman to its Board of Directors

Larimar Therapeutics Receives FDA Clearance to Proceed to 50 mg Cohort in CTI-1601's Phase 2 Friedreich's Ataxia Trial

Larimar Therapeutics, Inc. Announces Chief Medical Officer Changes

Here's Why We're Not Too Worried About Larimar Therapeutics' (NASDAQ:LRMR) Cash Burn Situation

Larimar Therapeutics Reports Preliminary Top-Line Data from Phase 2 Trial’S 25 Mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’S Ataxia

Larimar Therapeutics, Inc. Appoints Gopi Shankar as Chief Development Officer

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

Price target decreased to US$10.59

High number of new and inexperienced directors

Laramar Therapeutics issued patent for lead pipeline candidate

CEO, President & Director recently bought US$100k worth of stock

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

Larimar Therapeutics prices ~$70M stock offering

Price target increased to US$6.23

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Deliver On Growth Plans?

Larimar Therapeutics, Inc. Provides Updates on CTI-1601 Clinical Program Following A Type C Meeting with the U.S. Food and Drug Administration

Larimar Therapeutics GAAP EPS of -$0.47

Price target increased to US$5.88

High number of new and inexperienced directors

Larimar Therapeutics, Inc., Annual General Meeting, May 10, 2022

Larimar Therapeutics, Inc. Announces Not Stand for Re-Election of Thomas O. Daniel as Board of Director

We Think Larimar Therapeutics (NASDAQ:LRMR) Needs To Drive Business Growth Carefully

Price target decreased to US$13.50

Larimar Therapeutics, Inc. Provides Update on CTI-1601 Clinical Program

Is Larimar Therapeutics (NASDAQ:LRMR) In A Good Position To Invest In Growth?

Independent Director recently bought US$496k worth of stock

Larimar Therapeutics, Inc. Reports FDA Clinical Hold on CTI-1601

Larimar under pressure as FDA puts clinical hold on CTI-1601 program

Larimar Therapeutics, Inc. announced that it expects to receive $95.273757 million in funding from Deerfield Management Company, L.P. and other investors

Larimar Therapeutics, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for CTI-1601 in Friedreich’s Ataxia

Larimar Therapeutics Reports Positive Topline Phase 1 Clinical Trial Data Showing Dose-Dependent Increases in Frataxin Levels in Patients with Friedreich’s Ataxia

Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth

New 90-day low: US$17.75

Larimar, Avadel, Applied Therapeutics will added to Nasdaq Biotechnology Index

Larimar Therapeutics Announces Completion of Dosing of the Single Ascending Dose Clinical Trial in Friedreich’s Ataxia Patients and Provides Program Update

Larimar completes dosing in Friedreich’s Ataxia, provides program update

Larimar Therapeutics (LRMR) Investor Presentation - Slideshow

New 90-day high: US$22.50

Larimar Therapeutics reports Q3 results

Larimar Therapeutics Announces Formation of Scientific Advisory Board

New 90-day high: US$18.91

New 90-day high - US$16.00

Larimar Therapeutics, Inc.(NasdaqGM:LRMR) dropped from Russell Microcap Value Index

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간